The company’s lead product candidate, VDMN, offers the potential to transform the standard of care for common warts (verruca vulgaris), which affect 19 million Americans and are responsible for millions of clinical visits in the U.S. every year. There are no FDA approved prescription treatments for common warts. VDMN is a novel, injection-free approach to treating common warts in the form of a dissolvable microarray patch incorporating Candida Antigen Extract — which has been successfully used to treat warts for over 20 years with efficacy that exceeds current standard of care. VDMN is painlessly applied to the wart and worn for less than five minutes.

​

Applications are repeated every three weeks until wart resolution. Because of VDMN’s unique immunologic mechanism of action, patients suffering from multiple warts may only have to treat a single wart to treat all their warts. Because VDMN is a potential first licensure biologic with pediatric labeling, it can expect 12.5 years of regulatory exclusivity after BLA approval. Additionally, VDMN is protected by a broad portfolio of IP that covers the microarray technology and formulation.